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Iron Metabolism
Iron is an essential trace element, located with-
in each cell, the bulk of which is found in the eryth-
rocytes. Erythrocytes are produced in the bone mar-
row and after a 120-day long lifespan they are de-
stroyed in the spleen where iron is released. Most 
of the iron, used for the production of new erythro-
cytes, comes from the breakdown of old erythrocytes 
and only a small portion of it is derived from the iron 
obtained through the digested food (19). A large part 
of the iron is being released with the exfoliated en-
terocytes, skin cell and urine. Additional losses are 
observed during the menstrual blood loss in females. 
The iron metabolism differs from the one of other 
minerals and trace elements in that its release from 
organism cannot be controlled in contrast to its ab-
sorption (20).
Theoretically, when the organism needs more 
iron, its absorption is increased, while, when the iron 
is sufficient, the absorption is limited (22). Iron is ab-
sorbed mainly in the duodenum via an active pro-
cess, through which, from the intestinal lumen, iron 
enters the mucous cell, from where it is being trans-
ported to the blood, when necessary (10). If the or-
ganism does not need iron, it is stored as ferritin in 
the intestinal cell. Two factors are considered to take 
part in controlling the iron absorption: the size of the 
iron stores, as well as the erythropoietic activity (17). 
Erythroid regulation is activated mainly when the 
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bone marrow suffers an acute need of iron, while the 
regulation of iron stores is responsible from main-
taining the iron balance through iron absorption 
control (20). 
The peptide hormone hepcidin is a negative 
regulator of iron metabolism, which inhibits iron 
transportation by binding with the iron channel - 
ferroportin, residing in the enterocytes and the re-
ticuloendothelial cells. It influences the iron mobili-
zation by the liver and spleen, as well as the transpla-
cental iron transfer during pregnancy (32).
CONSEQUENCES OF IRON DEFICIENCY
Cognitive Development
There is strong evidence that IDA (Iron Defi-
ciency Anemia), during the first few years of life, is 
associated with abnormal cognitive and motor devel-
opment, as well as with behavioral issues. Longitudi-
nal studies consistently show that children, who were 
anemic in early childhood, continue to have poor 
cognitive and motor development, plus unsatisfacto-
ry performance in school as well (18). Iron deficiency 
has been found in children suffering from attention 
deficit disorder. Iron concentration in the umbilical 
artery is of critical importance during fetal develop-
ment and is related to the IQ (Intelligence Quotient) 
of the child. Iron deficiency anemia is common, es-
pecially in females, and is associated with manifes-
tations of apathy, depression and rapid onset fatigue 
during physical activity (7).
IDA in infancy and early childhood is not like-
ly to be corrected by a subsequent iron therapy (36). 
Grantham-McGrego, Ani (2001) have researched the 
effect of iron supplementation on the cognitive de-
velopment of children over 2 years of age and have 
reached the conclusion that iron therapy has a bene-
ficial effect in older anemic children. In four studies 
with children iron therapy has had a positive effect; 
in other three studies the benefit was highly proba-
ble, while two studies show it has no effect whatso-
ever. In children under 2 years of age the casual con-
nection is controversial (18). However, according to 
the authors of this article, the results of many studies 
are difficult to construe, since the size of the studied 
groups is not large enough so as to lead to a reliable 
interpretation of the data.
Experimental studies with rats demonstrate 
that in different stages of life, various parts of the 
brain contain high concentration of iron. The afore-
mentioned studies show that iron deficiency in the 
brain depends on the period during which iron defi-
ciency occurs (29). 
Impact of IDA on the Immune System
Most pathogens need iron and other trace el-
ements, and thus have developed complex mecha-
nisms for acquiring them. Iron is required by the host 
for the modulation of an effective immune response 
as well (2). Experimental and clinical studies suggest 
an increased risk of infection during an existing iron 
deficiency, even though a small number of scientific 
reports state the opposite (2). The difficult interpre-
tation of many studies derives from the existence of 
additional circumstances such as poverty, malnutri-
tion and multiple micronutrient deficiencies, as well 
as the presence of infection (12). Nevertheless, based 
on a review of 13 random clinical trials, the Interna-
tional Nutritional Anemia Consultative Group (23), 
states that known benefits of iron supplementation 
are likely to outweigh the risk of adverse effects in 
regions with endemic malaria. In a random clini-
cal study conducted in Tanzania, infants with ma-
laria have been treated with Sulphadoxine-pyrimeth-
amine or placebo. Those, who received iron supple-
ments, were between 2 and 6 months of age. During 
the first year of their lives clinical malaria has been 
reduced by 59%, while the instances of severe ane-
mia have been reduced by 50% in the treated group, 
as opposed to the placebo group (31), which demon-
strates a significant impact of malaria on the anemic 
onset.
A study, conducted on Turkish children, con-
firms that iron deficiency influences the humoral-, 
cell- and non-specific immunity, as well as the cyto-
kine activity, which plays a key role in different stag-
es of the immune mechanisms (15).
Changes in Metabolism during Iron Deficiency
Many metabolic processes change during iron 
deficiency. The activity or concentration of various 
iron-containing enzymes in skeletal muscles and liv-
er are being decreased during IDA (11). The concen-
tration of the main regulators of glucose synthesis 
– the catecholamines epinephrine and norepineph-
rine, deviates from the norm in humans and rats 
with iron deficiency (26).
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Iron deficiency influences the neurotransmitter 
system as well. Beard (2001), points out that the do-
paminergic system, which is the main mediating sys-
tem of the central nervous system, is extremely sen-
sitive to changes of the iron status. There is evidence 
that serotonin and norepinephrine metabolism in 
rats also change during iron deficiency (28). 
One of the main effects of chronic iron defi-
ciency on the circulatory system is cardiac hypertro-
phy (27). It is assumed that myocardial hypertrophy 
is physiological, aiming at maintaining the oxygen 
supply to peripheral tissues in anemic animals (33).
Some of the undesired side effects of iron defi-
ciency may be attributed to the presence of anemia, 
while others are more directly related to the decrease 
of iron in the organism, as well as to limitations in 
the tissue oxygen capacity (4). Nevertheless, differ-
entiating the after effects of decreased oxygen trans-
portation from iron deficiency in tissues is difficult, 
because tissue iron deficiency occurs simultaneous-
ly with the decrease of oxygen transportation in hu-
mans with IDA (2).
Biochemical Indicators for Iron Deficiency 
Evaluation
A series of laboratory indicators can be used to 
characterize iron status precisely and to categorize 
the severity of iron deficiency. Three levels of iron de-
ficiency are customarily identified:
 ❖ depleted iron stores, but where there appears 
to be no limitation in the supply of iron to the 
functional compartment;
 ❖ early functional iron deficiency (iron-deficient 
erythropoiesis) where the supply of iron to the 
functional compartment is suboptimal but not 
reduced sufficiently to cause measurable ane-
mia; and
 ❖ iron deficiency anemia, where there is a mea-
surable deficit in the most accessible functional 
compartment, the erythrocyte (14).
STORAGE IRON DEPLETION
Serum Ferritin Concentration.
Cellular iron, which is not immediately need-
ed for functional compounds, is stored in the form 
of ferritin. Small quantities of ferritin also circulate 
in the blood. The concentration of plasma and serum 
ferritin is proportional to the size of body iron stores 
in healthy individuals and those with early iron defi-
ciency. In an adult, each 1 μg/L of serum ferritin in-
dicates the presence of about 8 mg of storage iron (6). 
A similar relationship is present in children in that 
each 1 μg/L of serum ferritin is indicative of an iron 
store of about 0.14 mg/kg (16). When the serum ferri-
tin concentration falls below 15 μg/L, the iron stores 
are totally depleted (36). 
Serum ferritin concentrations are known to be 
affected by factors other than the size of iron stores. 
The concentrations are increased in the presence of 
infections, inflammatory disorders, cancers, and 
liver disease because ferritin is an acute phase pro-
tein (35). Thus, serum ferritin concentration may fall 
within the normal range in individuals who have no 
iron stores. It is increased during alcohol intake and 
hyperglycemia as well, and is directly related to the 
body mass index (BMI) (21). 
Despite the influence of various unrelated fac-
tors on serum ferritin concentration, this indicator is 
the most sensitive one for the amount of iron in the 
storage compartment.
Total Iron-Binding Capacity 
Iron is transported in the plasma and extracel-
lular fluid bound to transferrin. This metalloprotein 
has a very high affinity for iron. Virtually all plas-
ma iron is bound to transferrin. Therefore it is con-
venient to measure plasma transferrin concentra-
tion indirectly by quantifying the total iron-binding 
capacity (TIBC), which is the total quantity of iron 
bound to transferrin after the addition of exogenous 
iron to plasma. TIBC is elevated with iron storage 
depletion before there is evidence of inadequate de-
livery of iron to erythropoetic tissue. An increased 
TIBC (> 400 μg/dL) is therefore indicative of storage 
iron depletion. It is less precise than the serum ferri-
tin concentration. About 30 to 40 percent of individ-
uals with iron deficiency anemia have TIBCs that are 
not elevated (30). TIBC is reduced during infectious, 
inflammatory, or neoplastic disorders (25). 
Early Iron Deficiency
Early iron deficiency is signaled by evidence 
indicating that the iron supply to the bone marrow 
and other tissues is only marginally adequate. A 
measurable decrease in the hemoglobin concentration 
is not yet present and therefore there is no anemia 
(14).
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Serum Transferrin Saturation 
As the iron supply decreases, the serum iron 
concentration falls and the saturation of transferrin 
is decreased. Levels below 16 percent saturation indi-
cate that the rate of delivery of iron is insufficient to 
maintain the normal rate of hemoglobin synthesis. 
Low saturation levels are not specific for iron defi-
ciency and are encountered in other conditions such 
as anemia of chronic disease (13), which is associated 
with impaired release of iron from stores.
Erythrocyte Protoporphyrin Concentration 
Heme is formed in developing erythrocytes by 
the incorporation of iron into protoporphyrin IX by 
ferrochetalase. If there is insufficient iron for opti-
mal hemoglobin synthesis, erythrocytes accumulate 
an excess of protoporphyrin, which remains in the 
cells for the duration of their lifespans (13). An in-
creased erythrocyte protoporphyrin concentration 
in the blood therefore indicates that the erythrocytes 
matured at a time when the iron supply was subopti-
mal. The cut off concentration for erythrocyte proto-
porphyrin concentration is greater than 70 μg/dL of 
erythrocytes (8). 
Soluble Serum Transferrin Receptor 
Concentration 
The surfaces of all cells express transferrin re-
ceptors in proportion to their requirement for iron. A 
truncated form of the extracellular component of the 
transferrin receptor is produced by proteolytic cleav-
age and released into the plasma in direct proportion 
to the number of receptors expressed on the surfaces 
of body tissues. As functional iron depletion occurs, 
more transferrin receptors appear on cell surfaces. 
The concentration of proteolytically cleaved extra-
cellular domains, or soluble serum transferrin recep-
tors (sTfR), increases parallel to this. The magnitude 
of the increase is proportional to the functional iron 
deficit. The sTfR concentration appears to be a spe-
cific and sensitive indicator of early iron deficiency 
(1). sTfR is not influenced by inflammatory diseas-
es (34). 
Because commercial assays for sTfR have be-
come available only recently, there is a lack of data 
relating iron intake to sTfR concentration, as well as 
relating sTfR concentration to functional outcomes. 
This indicator may prove to be very useful in iden-
tifying iron deficiency, especially in patients who 
have concurrent infections or other inflammatory 
disorders.
Iron Deficiency Anemia
Anemia is the most easily identifiable indica-
tor of functional iron deficiency. As discussed above, 
physiological impairment occurs at this stage of iron 
deficiency both because of inadequate oxygen deliv-
ery during exercise and because of abnormal enzyme 
function in tissues (14).
Hemoglobin Concentration and Hematocrit 
The hemoglobin concentration or hematocrit is 
neither a sensitive, nor a specific indicator of mild, 
yet functionally significant, iron deficiency anemia. 
Iron deficiency anemia is microcytic (reduced mean 
erythrocyte volume and mean erythrocyte hemoglo-
bin). However, microcytic anemia is characteristic of 
all anemias in which the primary abnormality is im-
paired hemoglobin synthesis. Iron deficiency is only 
one of the potential causal factors. The diagnosis of 
iron deficiency anemia, based solely on the presence 
of anemia, can result in misdiagnosis in many cas-
es (14).
Erythrocyte Indexes 
Iron deficiency leads to the formation of small 
erythrocytes. Mean corpuscular hemoglobin (MCH) 
is the amount of hemoglobin in erythrocytes. The 
mean corpuscular volume (MCV) is the volume of 
the average erythrocyte. Both MCH and MCV are 
reduced in iron deficiency, but their values are not 
specific for it. They occur in all conditions that cause 
impaired hemoglobin synthesis, particularly the 
thalassemias (9). 
Iron deficiency is particularly common among 
risk population groups such as children, adolescents, 
pregnant and lactating women, as well as elderly 
people.
Our studies on pregnant women demonstrate 
that ferritin in 69% of them is below 15 μg/L, with 
the highest percentage in the third trimester, while 
hemoglobin in 36.7% of them is below 110 g/L (4) – a 
criterion for iron deficiency during pregnancy (24).
Results from our studies on pregnant women 
show significant correlation among the indicators of 
iron homeostasis: significant negative correlation be-
tween sTfR/SF (R=-0.460, p<0.0001), sTfR/Нb (R=-
0.302, p=0.002), and a positive one between Нb/SF 
(R=0.389, p<0.0001) as compared to the controls, in 
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which those dependencies are lost (p>0.05). The ges-
tation period has a significant impact on the level of 
all iron indicators with a lowering of Hb and SF and 
elevation of sTfR during pregnancy (3).
These results reflect the increased iron needs in 
relation to nutrition and fetus growth, as well as an 
iron deficiency tendency, which is most prominent 
during the last months of pregnancy (3).
CONCLUSION
Iron deficiency has a wide range of adverse ef-
fects on health. While it is not the sole reason for ane-
mic onset, iron deficiency is the most common caus-
al factor for anemia. Iron deficiency develops in three 
overlapping stages. The three main places where iron 
resides – the stores, the transported iron and the ery-
throid iron, are consecutively affected by a rising de-
ficiency of this trace element in the organism. Se-
rum ferritin concentration is considered to be the 
most practical and sensitive indicator, which corre-
lates with the level of all iron stores in the organism. 
sTfR is the first laboratory criterion of iron deficien-
cy after the depletion of the iron stores. Hemoglobin 
determines a more advanced stage of the absence of 
iron and this is a quantitative measure of the iron de-
ficiency severity, when anemia is already present.
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